[go: up one dir, main page]

RU2008133932A - CELLULAR Adenocarcinoma CELL LINE SKOV-KAT - Google Patents

CELLULAR Adenocarcinoma CELL LINE SKOV-KAT Download PDF

Info

Publication number
RU2008133932A
RU2008133932A RU2008133932/13A RU2008133932A RU2008133932A RU 2008133932 A RU2008133932 A RU 2008133932A RU 2008133932/13 A RU2008133932/13 A RU 2008133932/13A RU 2008133932 A RU2008133932 A RU 2008133932A RU 2008133932 A RU2008133932 A RU 2008133932A
Authority
RU
Russia
Prior art keywords
kat
cell line
adenocarcinoma cell
cellular
line skov
Prior art date
Application number
RU2008133932/13A
Other languages
Russian (ru)
Other versions
RU2404244C2 (en
Inventor
Дмитрий Владимирович Карпенко (RU)
Дмитрий Владимирович Карпенко
Олег Анатольевич Стремовский (RU)
Олег Анатольевич Стремовский
Сергей Михайлович Деев (RU)
Сергей Михайлович Деев
Original Assignee
Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU)
Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU), Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН filed Critical Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (RU)
Priority to RU2008133932/10A priority Critical patent/RU2404244C2/en
Publication of RU2008133932A publication Critical patent/RU2008133932A/en
Application granted granted Critical
Publication of RU2404244C2 publication Critical patent/RU2404244C2/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Клеточная линия аденокарциномы яичника человека SKOV-kat, гиперэкспрессирующая онкомаркер HER2/neu и флуоресцирующая в дальней красной области спектра 600-700 нм, для использования в скрининге противоопухолевых препаратов in vivo.The human ovarian adenocarcinoma cell line SKOV-kat, which overexpresses the HER2 / neu tumor marker and fluoresces in the far red spectral region 600-700 nm, for use in in vivo screening of anticancer drugs.

Claims (1)

Клеточная линия аденокарциномы яичника человека SKOV-kat, гиперэкспрессирующая онкомаркер HER2/neu и флуоресцирующая в дальней красной области спектра 600-700 нм, для использования в скрининге противоопухолевых препаратов in vivo. The human ovarian adenocarcinoma cell line SKOV-kat, which overexpresses the HER2 / neu tumor marker and fluoresces in the far red spectral region 600-700 nm, for use in in vivo screening of anticancer drugs.
RU2008133932/10A 2008-08-20 2008-08-20 STABLE CELL LINE OF HUMAN OVARIAN ADENOCARCINOMA SKOV-kat RU2404244C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2008133932/10A RU2404244C2 (en) 2008-08-20 2008-08-20 STABLE CELL LINE OF HUMAN OVARIAN ADENOCARCINOMA SKOV-kat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2008133932/10A RU2404244C2 (en) 2008-08-20 2008-08-20 STABLE CELL LINE OF HUMAN OVARIAN ADENOCARCINOMA SKOV-kat

Publications (2)

Publication Number Publication Date
RU2008133932A true RU2008133932A (en) 2010-02-27
RU2404244C2 RU2404244C2 (en) 2010-11-20

Family

ID=42127494

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008133932/10A RU2404244C2 (en) 2008-08-20 2008-08-20 STABLE CELL LINE OF HUMAN OVARIAN ADENOCARCINOMA SKOV-kat

Country Status (1)

Country Link
RU (1) RU2404244C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110244502A1 (en) 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
JP2014508540A (en) * 2011-03-24 2014-04-10 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Compositions and methods for culturing cells from normal human tubular ovarian epithelium and human tubular ovarian tumors
RU2709675C1 (en) * 2018-11-15 2019-12-19 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Stable human breast cancer carcinoma cell line skbr-kat

Also Published As

Publication number Publication date
RU2404244C2 (en) 2010-11-20

Similar Documents

Publication Publication Date Title
CY1119324T1 (en) ANTIBODIES AGAINST CSF-1R
CY1119591T1 (en) SPECIAL CONNECTION PROTEINS AND THEIR USES
CY1119129T1 (en) ANHYDRATE CRYSTAL FORM OF DIETHOXY DOXACEL AND ITS PRODUCTION PROCEDURES
CY1122161T1 (en) ANTI-CD38 CONJUGATED ANTIBODIES
ES2534430T3 (en) Modulation method of epidermal growth factor receptor (EGFR) expression that involves miRNA
EA201790404A1 (en) MACROPINOCYTOZING HUMAN ANTI-CD46 ANTIBODIES AND TARGET TREATMENT OF CANCER
CY1118608T1 (en) ANTIBODIES FOR CLAUDINE-expressing CANCER 6
CL2016002359A1 (en) Antibodies that bind to human epidermal growth receptor (anti-egfr) and anti-egfr antibody and drug conjugates
WO2012040459A3 (en) Beta-catenin targeting peptides and uses thereof
CY1117031T1 (en) CLAUDIN-18 Monoclonal Antibodies In Cancer Treatment
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
MX346924B (en) DIARILHIDANTOINE COMPOUNDS.
BR112016015848A2 (en) COMPOUND, COMBINATION OF A COMPOUND AND, PHARMACEUTICAL COMPOSITION
MX2013002084A (en) Biomarkers and methods of treatment.
NI201200175A (en) BLADDER CANCER TREATMENT METHODS
MX374463B (en) ANTI-EGFR ANTIBODIES AND THEIR USES.
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EA201390472A1 (en) NEW MOLECULES CONNECTING WITH EGFR AND THEIR IMMUNOCONJUGATES
MX347893B (en) Human antibody drug conjugates against tissue factor.
CL2011003052A1 (en) Compound 8- (2,4-dimethoxy-pyrimidin-5-yl) -1- (1-ethyl-3-methyl-1h-pyrazol-4-yl) -3-methyl-1,3-dihydro-imidazo [4 , 5-c] quinolin-2-one; its pharmaceutical composition; Useful in the treatment of lipid and / or protein kinase dependent diseases, in the treatment of proliferative diseases, such as tumors and carcinomas of the brain, kidney, liver, among others.
EA201101651A1 (en) CONTINUOUS INTRODUCTION OF INTEGRINE LIGANDS FOR CANCER TREATMENT
WO2009004484A3 (en) Trim24 (tifla) as p53 modulator and cancer target
EA201691053A1 (en) CONNECTIONS TO THE RECEPTOR OF THE GROWTH FACTOR FACTOR OF 3 TYPE FIBROBLASTES (FGFR3) AND METHODS OF THERAPY
MX336761B (en) Compounds for treatment of cancer.
WO2009020645A3 (en) Matriptase protein and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170821

NF4A Reinstatement of patent

Effective date: 20180718